Alyeska Investment Group
FOLD

Alyeska Investment Group’s Amicus Therapeutics FOLD Stock Holding History

Alyeska Investment Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-103,304
Closed -$1.61M – 437
2018
Q2 		$1.61M Buy
103,304
+3,304
+3% +$49.9K 0.01% 367
2018
Q1 		$1.5M Buy
+100,000
New +$1.52M 0.01% 370

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alyeska Investment Group's FOLD Position: Q3 2018 in Review

Alyeska Investment Group sold out of Amicus Therapeutics (FOLD) in Q3 2018, closing a stake of 103,304 shares — an estimated $1.61M sold.

Alyeska Investment Group first reported a position in FOLD in Q1 2018 and held it in 2 quarters. The position peaked at $1.61M in Q2 2018. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2018.

  • Alyeska Investment Group reported no remaining Amicus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 103,304 Amicus Therapeutics shares in Q3 2018, an estimated $1.61M.
  • Alyeska Investment Group first reported a position in Amicus Therapeutics in Q1 2018 and held it in 2 quarters.
  • Alyeska Investment Group's Amicus Therapeutics position peaked at $1.61M in Q2 2018.
  • 204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.